Maeda Makiko

マエダマキコ | Maeda Makiko

Affiliation and department：

Research field (1)： Clinical pharmacy

Research keywords (1)：医療薬学

Research theme for competitive and other funds (6)：

2022 - 2025 抗凝固薬の有効性及び安全性の予測モデル構築のための基盤研究~社会実装を目指して
2019 - 2023 ゲノム薬理学を応用した国際共同臨床研究推進のための基盤構築
2018 - 2021 Molecular mechanisms of cell proliferation of adult mammalian cardiomyocytes
2008 - 2010 The study for the effects of Interluekin-11on cardiac remodeling following myocardial infarction.
2008 - 2009 科学的根拠に基づいた禁煙支援を目指して

Show all

Papers (114)：

Yoshiaki Miyake, Masanori Obana, Ayaha Yamamoto, Shunsuke Noda, Koki Tanaka, Hibiki Sakai, Narihito Tatsumoto, Chihiro Makino, Soshi Kanemoto, Go Shioi, et al. Upregulation of OASIS/CREB3L1 in podocytes contributes to the disturbance of kidney homeostasis. Communications Biology. 2022. 5. 1
Kazuma Higashisaka, Sonoko Takeya, Haruhiko Kamada, Masanori Obana, Makiko Maeda, Mai Kabayama, Koichi Yamamoto, Nanan Ishida, Ryo Isaka, Hirofumi Tsujino, et al. Identification of biomarkers of chronic kidney disease among kidney-derived proteins. Clinical Proteomics. 2022. 19. 1
Masashi Tomimatsu, Kotaro Matsumoto, Moe Ashizuka, Shohei Kumagai, Shota Tanaka, Takafumi Nakae, Kosei Yokota, Shunsuke Kominami, Ryota Kajiura, Daisuke Okuzaki, et al. Myeloid cell-specific ablation of Runx2 gene exacerbates post-infarct cardiac remodeling. Scientific reports. 2022. 12. 1. 16656-16656
Masanori Obana, Makiko Maeda, Yasushi Fujio. Glycoprotein 130 orchestrates signal transduction network to promote cardiomyocyte proliferation for normal growth. American Journal of Physiology-Heart and Circulatory Physiology. 2022. 323. 1. H125-H127
Tri Wahyuni, Shota Tanaka, Ryuta Igarashi, Yoshiaki Miyake, Ayaha Yamamoto, Shota Mori, Yusuke Kametani, Masashi Tomimatsu, Shota Suzuki, Kosei Yokota, et al. CXCL10 is a novel anti-angiogenic factor downstream of p53 in cardiomyocytes. Physiological reports. 2022. 10. 9. e15304

ｍore...

MISC (100)：

尾花理徳, 山本彩葉, 中江崇文, 三宅芳明, 原田雄生, 光岡小百合, 前田真貴子, 今泉和則, 松本浩太朗, 藤尾慈. 転写因子Old Astrocyte Specifically Induced Substance(OASIS)は新規腎線維化制御因子である. 第29回日本循環薬理学会第55回高血圧関連疾患モデル学会合同学会. 2019
Masanori Obana, Ayaha Yamamoto, Takafumi Nakae, Yoshiaki Miyake, Takeo Harada, Sayuri Mitsuoka, Shunsuke Noda, Makiko Maeda, Kazunori Imaizumi, Kotaro Matsumoto, et al. Suppression of transcription factor OASIS ameliorated kidney fibrosis. ASN Kidney Week 2019 Annual Meeting. 2019
Kotaro Matsumoto, Masanori Obana, Arisa Kobayashi, Miho Kihara, Go Shioi, Shigeru Miyagawa, Makiko Maeda, Yasushi Sakata, Hiroyuki Nakayama, Yoshiki Sawa, et al. Blockade of NKG2D / NKG2D Ligand Interaction Attenuated Post-Infarct Myocardial Injury. CIRCULATION. 2018. 138
尾花理徳, 守沖瞳, 山本彩葉, 金本聡自, 前田真貴子, 今泉和則, 中山博之, 藤尾慈. 転写因子OASISは筋線維芽細胞の増殖,遊走を介して腎線維化に関与する. 日本腎臓学会誌. 2018. 60. 3. 434-434
加藤千晴, 前田真一郎, 前田真貴子, 三輪芳弘, 上島悦子, 藤尾慈. リツキサンのInfusion Reaction発現に関わる予測因子の探索. 日本薬学会年会要旨集. 2018. 138年会. 4. 128-128

ｍore...

Patents (4)：

Education (1)：

- 2005 Osaka University

Committee career (4)：

2020/04 - 現在医療法人平心会 IRB/セントラルIRB
2020/04 - 現在医療法人平心会倫理審査委員会
2018/04 - 現在大阪大学薬学研究科研究倫理委員
2009/12 - 2015/03 医療法人協和会千里中央病院倫理委員会治験審査委員

Association Membership(s) (4)：

THE JAPANESE PHARMACOLOGICAL SOCIETY , American Heart Association , THE PHARMACEUTICAL SOCIETY OF JAPAN , THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page